Moazzam Shahzad, Hematologist-Oncologist at H. Lee Moffitt Cancer Center and Research Institute, shared a post on X about a paper he co-authored with colleagues published in Clinical Lymphoma Myeloma and Leukemia:
“Our recent publication in CLML explores the impact of MRD status after matched donor alloHCT in AML.”
Title: Impact of Measurable Residual Disease Status on Outcomes after HLA-Matched Donor Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia
Authors: Moazzam Shahzad, Muhammad Kashif Amin, Sohaib Irfan, Abhinav Vyas, Rania Ahsan, Sibgha Gull Chaudhary, Iqra Anwar, Matthew McGuirk, Raheel Iftikhar, Haitham Abdelhakim, Anurag K. Singh, Mehdi Hamadani, Joseph P. Mcguirk, Muhammad Umair Mushtaq
You can read the Full Article on Clinical Lymphoma Myeloma and Leukemia.
More posts featuring Moazzam Shahzad.